Can Canopy Growth Stock Compete in the U.S.?

One of the latest debates among cannabis investors is how Canadian cannabis companies like Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) will effectively compete against U.S. players like Curaleaf (TSXV:CURA).

| More on:
Cannabis stocks have fallen.

There’s no doubt that Canopy Growth (TSX:WEED)(NYSE:CGC) is one of the best stocks in the cannabis sector. Investors are more excited than ever about Federal U.S. cannabis legalization, buoying all stocks in this sector in recent months. Canopy Growth stock is no exception.

However, some of its peers, namely Curaleaf Holdings (TSXV:CURA), are ahead of the curve in this regard. Recently, Canopy made a big move in the United States. But will that be enough to topple the other players in the market? Let’s find out.

Steps taken to gain market share in the U.S.

This Smith Falls-based company announced that it would be introducing four new cannabis-infused drinks in the United States. Its Quatreau products will contain 20 grams of CBD oil and will be sold online in four flavours. The company believes that there is ample scope for growth, as Canadians and Americans have almost identical consumer preferences. I believe that this could be a significant opportunity, as cannabis laws are overhauled by the Democrats.

Square and New Frontier Data reports suggest that $121 billion will be spent on CBD oil between 2020 and 2025 in the United States. Moreover, the predictions indicate that consumers aged between 34 and 44 years will fuel the expenses.

As per Canopy’s research, two out of three Americans who are aware of CBD oil cannot name more than one producer. I believe that the highly fragmented market will play out in its favour, as Canopy is a recognized brand with a proven formula.

A promising move, but more work to be done

Canopy has definitely taken a step forward in the right direction. However, when it comes to the U.S. THC market, Curaleaf has a significant head start. Curaleaf’s the big dog in a relatively small but booming town. This has been reflected in the sharp 400% increase in the company’s stock price since 2020 lows. Additionally, with a Democratic sweep of the House and Senate, I think federal legalization is just a matter of time. Indeed, I’m convinced that there’s a great opportunity for Curaleaf to dominate the U.S. cannabis market.

Contrary to most Canadian peers, Curaleaf has built what appears to be an efficient and sustainable vertically integrated business model. It engages in the manufacturing of value-added products, which enhances its margins across the board. Furthermore, it appears this company has a management team that’s doing all the right things to promote long-term growth. I like that.

Indeed, I think Canopy will ultimately be playing an expensive game of catch-up to peers like Curaleaf.

Bottom line on Canopy Growth stock

Canopy Growth remains a top player in the cannabis market. However, the stock’s growth rate has been sluggish compared to its peers. This might be due to a pervasive belief that U.S.-fixed companies will outperform, whereas Canada-focused companies will lag.

Accordingly, right now, my top pick in the cannabis space is Curaleaf. Canopy’s a great company, but I think Curaleaf’s growing lead is going to be very hard to overcome.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. Tom Gardner owns shares of Square. The Motley Fool owns shares of and recommends Square.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

2 Cannabis Stocks I’d Buy Over Canopy Growth

Here's why these two cannabis stocks are better long-term investments compared to Canopy Growth stock in 2023.

Read more »

edit Jars of marijuana
Cannabis Stocks

A Dividend Giant I’d Buy Over Canopy Growth Stock

Forget investing in a fundamentally weak stock such as Canopy Growth and buy shares of this cannabis REIT instead.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Corp: The Bottom Isn’t In

Canopy Growth Corp (TSX:WEED) is hitting new lows. Unfortunately, the bottom probably isn't in.

Read more »

edit Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Is Canopy Growth Stock a Buy in September?

Canopy Growth stock (TSX:WEED) has seen some major movement recently, with good news from the US boosting it further.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Will Canopy Growth Stock Continue to Surge in September 2023?

Canopy Growth stock has surged over 70% in the past week. Is WEED stock a good buy right now?

Read more »

A cannabis plant grows.
Cannabis Stocks

Is Canopy Growth Stock Worth a Buy in September?

Here's the bull and bear case behind whether Canopy Growth (TSX:WEED) stock is worth a speculative buy in September or…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Why Cannabis Stocks Are Flying Higher Again Today

Here’s why cannabis stocks, including TLRY, CRON, and ACB, are skyrocketing this week.

Read more »

A cannabis plant grows.
Cannabis Stocks

If You’d Invested $10,000 in Canopy Growth Stock When Cannabis Became Legal, Here’s What You’d Be Left with Today

A large investment in Canopy Growth Corp. (TSX:WEED) when cannabis was legalized may have seemed like a good idea at…

Read more »